Semaglutide, found in medications like Ozempic, Rybelsus, and Wegovy, has been under scrutiny for its potential side effects. Notably, the European Medicines Agency's PRAC released findings on June 6, 2025, indicating that Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) is a very rare but serious complication associated with Semaglutide treatments. NAION can lead to sudden vision loss, raising concerns for patients. Although the occurrence is infrequent, it is crucial for healthcare providers and patients to discuss the risks thoroughly. Based on the PRAC's conclusions, treatment with Semaglutide should be halted if any symptoms of NAION develop. Symptoms may include a sudden decrease in vision, particularly in one eye, which warrants immediate medical attention. As awareness regarding these potential side effects increases, patients using these medications are encouraged to monitor their vision and have open conversations with their healthcare professionals about any concerns. In addition to NAION, other side effects reported include gastrointestinal disturbances, which can affect patient compliance with the medication regimen. Proper education on both the benefits and risks of Semaglutide is essential to ensure that patients can make informed decisions about their health and treatment options. As with any medication, individual risk factors and health history should guide the safety and effectiveness of Semaglutide for weight management and diabetes control.